Antibody-mediated enhancement of parvovirus B19 uptake into endothelial cells mediated by a receptor for complement factor C1q

Journal of Virology

Volumn 88, Issue 14, 2014, Pages 8102-8115

  von Kietzell, Kristina ^a   Pozzuto, Tanja ^b   Heilbronn, Regine ^a   Grössl, Tobias ^b   Fechner, Henry ^b   Weger, Stefan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b TECHNISCHE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT FACTOR; COMPLEMENT FACTOR C1Q; FC RECEPTOR; IMMUNOGLOBULIN G; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RECEPTOR;

ANTIBODY DEPENDENT ENHANCEMENT; ANTIGEN EXPRESSION; ARTICLE; BINDING AFFINITY; BINDING SITE; CELL SURFACE; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HUMAN PARVOVIRUS B19; IMMUNE RESPONSE; MOLECULAR DYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; VIRAL TROPISM; VIRUS ATTACHMENT; VIRUS CELL INTERACTION; VIRUS ENTRY;

ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; CELL LINE; ENDOTHELIAL CELLS; HEALTHY VOLUNTEERS; HUMANS; MEMBRANE GLYCOPROTEINS; PARVOVIRUS B19, HUMAN; RECEPTORS, COMPLEMENT; RECEPTORS, VIRUS; VIRUS INTERNALIZATION;

EID: 84904693024     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00649-14     Document Type: Article

References (68)

1. Cossart YE, Field AM, Cant B, Widdows D. 1975. Parvovirus-like particles in human sera. Lancet i:72-73.
2. Ozawa K, Kurtzman G, Young N. 1986. Replication of the B19 parvovirus in human bone marrow cell cultures. Science 233:883-886. http://dx.doi.org/10.1126/science.3738514.
3. Srivastava A, Lu L. 1988. Replication of B19 parvovirus in highly enriched hematopoietic progenitor cells from normal human bone marrow. J. Virol. 62:3059-3063.
4. Young NS, Brown KE. 2004. Parvovirus B19. N. Engl. J. Med. 350:586-597. http://dx.doi.org/10.1056/NEJMra030840.
5. Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, Pattison JR, Tyrrell DA. 1985. Experimental parvoviral infection in humans. J. Infect. Dis. 152:257-265. http://dx.doi.org/10.1093/infdis/152.2.257.
6. Broliden K, Tolfvenstam T, Norbeck O. 2006. Clinical aspects of parvovirus B19 infection. J. Intern. Med. 260:285-304. http://dx.doi.org/10.1111/j.1365-2796.2006.01697.x.
7. Brown T, Anand A, Ritchie LD, Clewley JP, Reid TM. 1984. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet ii:1033-1034.
8. Knott PD, Welply GA, Anderson MJ. 1984. Serologically proved intrauterine infection with parvovirus. Br. Med. J. 289:1660. http://dx.doi.org /10.1136/bmj.289.6459.1660.
9. Kerr JR. 2000. Pathogenesis of human parvovirus B19 in rheumatic disease. Ann. Rheum. Dis. 59:672-683. http://dx.doi.org/10.1136/ard.59.9.672.
10. Moore TL. 2000. Parvovirus-associated arthritis. Curr. Opin. Rheumatol. 12:289-294. http://dx.doi.org/10.1097/00002281-200007000-00010.
11. Dingli D, Pfizenmaier DH, Arromdee E, Wennberg P, Spittell PC, Chang-Miller A, Clarke BL. 2000. Severe digital arterial occlusive disease and acute parvovirus B19 infection. Lancet 356:312-314. http://dx.doi.org /10.1016/S0140-6736(00)02512-5.
12. Finkel TH, Leung DYM, Harbeck RJ, Gelfand EW, Török TJ, Zaki SR, Anderson LJ, Ferguson PJ, Saulsbury FT, Durigon EL, Hollister JR. 1994. Chronic parvovirus B19 infection and systemic necrotising vasculitis: opportunistic infection or aetiological agent? Lancet 343:1255-1258. http://dx.doi.org/10.1016/S0140-6736(94)92152-0.
13. Barah F, Vallely PJ, Chiswick ML, Cleator GM, Kerr JR. 2001. Association of human parvovirus B19 infection with acute meningoencephalitis. Lancet 358:729-730. http://dx.doi.org/10.1016/S0140-6736(01)05905-0.
14. Drago F, Semino M, Rampini P, Rebora A. 1999. Parvovirus B19 infection associated with acute hepatitis and a purpuric exanthem. Br. J. Dermatol. 141:160-161. http://dx.doi.org/10.1046/j.1365-2133.1999.02943.x.
15. Yoto Y, Kudoh T, Haseyama K, Suzuki N, Chiba S. 1996. Human parvovirus B19 infection associated with acute hepatitis. Lancet 347:868-869. http://dx.doi.org/10.1016/S0140-6736(96)91348-3.
16. Bultmann BD, Klingel K, Sotlar K, Bock CT, Kandolf R. 2003. Parvovirus B19: a pathogen responsible for more than hematologic disorders. Virchows Arch. 442:8-17. http://dx.doi.org/10.1007/s00428-002-0732-8.
17. Nigro G, Bastianon V, Colloridi V, Ventriglia F, Gallo P, D'Amati G, Koch WC, Adler SP. 2000. Human parvovirus B19 infection in infancy associated with acute and chronic lymphocytic myocarditis and high cytokine levels: report of 3 cases and review. Clin. Infect. Dis. 31:65-69. http://dx.doi.org/10.1086/313929.
18. Schowengerdt KO, Ni J, Denfield SW, Gajarski RJ, Bowles NE, Rosenthal G, Kearney DL, Price JK, Rogers BB, Schauer GM, Chinnock RE, Towbin JA. 1997. Association of parvovirus B19 genome in children with myocarditis and cardiac allograft rejection: diagnosis using the polymerase chain reaction. Circulation 96:3549-3554. http://dx.doi.org/10.1161/01.CIR.96.10.3549.
19. Kuhl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, Poller W, Kandolf R, Schultheiss HP. 2005. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with "idiopathic" left ventricular dysfunction. Circulation 111:887-893. http: //dx.doi.org/10.1161/01.CIR.0000155616.07901.35.
20. Bultmann BD, Klingel K, Sotlar K, Bock CT, Baba HA, Sauter M, Kandolf R. 2003. Fatal parvovirus B19-associated myocarditis clinically mimicking ischemic heart disease: an endothelial cell-mediated disease. Hum. Pathol. 34:92-95. http://dx.doi.org/10.1053/hupa.2003.48.
21. Klingel K, Sauter M, Bock CT, Szalay G, Schnorr JJ, Kandolf R. 2004. Molecular pathology of inflammatory cardiomyopathy. Med. Microbiol. Immunol. 193:101-107. http://dx.doi.org/10.1007/s00430-003-0190-1.
22. Pasquinelli G, Bonvicini F, Foroni L, Salfi N, Gallinella G. 2009. Placental endothelial cells can be productively infected by Parvovirus B19. J. Clin. Virol. 44:33-38. http://dx.doi.org/10.1016/j.jcv.2008.10.008.
23. Filippone C, Zhi N, Wong S, Lu J, Kajigaya S, Gallinella G, Kakkola L, Soderlund-Venermo M, Young NS, Brown KE. 2008. VP1u phospholipase activity is critical for infectivity of full-length parvovirus B19 genomic clones. Virology 374:444-452. http://dx.doi.org/10.1016/j.virol.2008.01.002.
24. Lu J, Zhi N, Wong S, Brown KE. 2006. Activation of synoviocytes by the secreted phospholipase A2 motif in the VP1-unique region of parvovirus B19 minor capsid protein. J. Infect. Dis. 193:582-590. http://dx.doi.org/10.1086/499599.
25. Brown KE, Anderson SM, Young NS. 1993. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science 262:114-117. http://dx.doi.org/10.1126/science.8211117.
26. Weigel-Kelley KA, Yoder MC, Srivastava A. 2001. Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J. Virol. 75:4110-4116. http://dx.doi.org/10.1128/JVI.75.9.4110-4116.2001.
27. Zakrzewska K, Cortivo R, Tonello C, Panfilo S, Abatangelo G, Giuggioli D, Ferri C, Corcioli F, Azzi A. 2005. Human parvovirus B19 experimental infection in human fibroblasts and endothelial cells cultures. Virus Res. 114:1-5. http://dx.doi.org/10.1016/j.virusres.2005.05.003.
28. Weigel-Kelley KA, Yoder MC, Srivastava A. 2003. Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of beta1 integrin for viral entry. Blood 102:3927-3933. http://dx.doi.org/10.1182/blood-2003-05-1522.
29. Munakata Y, Saito-Ito T, Kumura-Ishii K, Huang J, Kodera T, Ishii T, Hirabayashi Y, Koyanagi Y, Sasaki T. 2005. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood 106:3449-3456. http://dx.doi.org/10.1182/blood-2005-02-0536.
30. Kaufmann B, Baxa U, Chipman PR, Rossmann MG, Modrow S, Seckler R. 2005. Parvovirus B19 does not bind to membrane-associated globoside in vitro. Virology 332:189-198. http://dx.doi.org/10.1016/j.virol.2004.11.037.
31. Brunstein J, Soderlund-Venermo M, Hedman K. 2000. Identification of a novel RNA splicing pattern as a basis of restricted cell tropism of erythrovirus B19. Virology 274:284-291. http://dx.doi.org/10.1006/viro.2000.0460.
32. Liu JM, Green SW, Shimada T, Young NS. 1992. A block in full-length transcript maturation in cells nonpermissive for B19 parvovirus. J. Virol. 66:4686-4692.
33. Pallier C, Greco A, Le Junter J, Saib A, Vassias I, Morinet F. 1997. The 3' untranslated region of the B19 parvovirus capsid protein mRNAs inhibits its own mRNA translation in nonpermissive cells. J. Virol. 71:9482-9489.
34. Gallinella G, Manaresi E, Zuffi E, Venturoli S, Bonsi L, Bagnara GP, Musiani M, Zerbini M. 2000. Different patterns of restriction to B19 parvovirus replication in human blast cell lines. Virology 278:361-367. http://dx.doi.org/10.1006/viro.2000.0673.
35. Guan W, Cheng F, Yoto Y, Kleiboeker S, Wong S, Zhi N, Pintel DJ, Qiu J. 2008. Block to the production of full-length B19 virus transcripts by internal polyadenylation is overcome by replication of the viral genome. J. Virol. 82:9951-9963. http://dx.doi.org/10.1128/JVI.01162-08.
36. Chen AY, Guan W, Lou S, Liu Z, Kleiboeker S, Qiu J. 2010. Role of erythropoietin receptor signaling in parvovirus B19 replication in human erythroid progenitor cells. J. Virol. 84:12385-12396. http://dx.doi.org/10.1128/JVI.01229-10.
37. Munshi NC, Zhou S, Woody MJ, Morgan DA, Srivastava A. 1993. Successful replication of parvovirus B19 in the human megakaryocytic leukemia cell line MB-02. J. Virol. 67:562-566.
38. Shimomura S, Komatsu N, Frickhofen N, Anderson S, Kajigaya S, Young NS. 1992. First continuous propagation of B19 parvovirus in a cell line. Blood 79:18-24.
39. Wong S, Zhi N, Filippone C, Keyvanfar K, Kajigaya S, Brown KE, Young NS. 2008. Ex vivo-generated CD36+ erythroid progenitors are highly permissive to human parvovirus B19 replication. J. Virol. 82:2470-2476. http://dx.doi.org/10.1128/JVI.02247-07.
40. Hawkes RA. 1964. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust. J. Exp. Biol. Med. Sci. 42:465-482. http://dx.doi.org/10.1038/icb.1964.44.
41. Halstead SB, O'Rourke EJ. 1977. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265:739-741. http://dx.doi.org/10.1038/265739a0.
42. Robinson WE, Jr, Montefiori DC, Mitchell WM. 1988. Antibodydependent enhancement of human immunodeficiency virus type 1 infection. Lancet i:790-794.
43. Takada A, Feldmann H, Ksiazek TG, Kawaoka Y. 2003. Antibodydependent enhancement of Ebola virus infection. J. Virol. 77:7539-7544. http://dx.doi.org/10.1128/JVI.77.13.7539-7544.2003.
44. Kanno H, Wolfinbarger JB, Bloom ME. 1993. Aleutian mink disease parvovirus infection of mink macrophages and human macrophage cell line U937: demonstration of antibody-dependent enhancement of infection. J. Virol. 67:7017-7024.
45. Munakata Y, Kato I, Saito T, Kodera T, Ishii KK, Sasaki T. 2006. Human parvovirus B19 infection of monocytic cell line U937 and antibody-dependent enhancement. Virology 345:251-257. http://dx.doi.org /10.1016/j.virol.2005.09.040.
46. Halstead SB, O'Rourke EJ, Allison AC. 1977. Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection. J. Exp. Med. 146:218-229.
47. Peiris JS, Gordon S, Unkeless JC, Porterfield JS. 1981. Monoclonal anti-Fc receptor IgG blocks antibody enhancement of viral replication in macrophages. Nature 289:189-191. http://dx.doi.org/10.1038/289189a0.
48. Cardosa MJ, Porterfield JS, Gordon S. 1983. Complement receptor mediates enhanced flavivirus replication in macrophages. J. Exp. Med. 158:258-263. http://dx.doi.org/10.1084/jem.158.1.258.
49. June RA, Schade SZ, Bankowski MJ, Kuhns M, McNamara A, Lint TF, Landay AL, Spear GT. 1991. Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. AIDS 5:269-274.
50. Nimmerjahn F, Ravetch JV. 2008. Fcgamma receptors as regulators of immune responses. Nat. Rev. Immunol. 8:34-47. http://dx.doi.org/10.1038/nri2206.
51. Takada A, Kawaoka Y. 2003. Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications. Rev. Med. Virol. 13:387-398. http://dx.doi.org/10.1002/rmv.405.
52. Nepomuceno RR, Tenner AJ. 1998. C1qRP, the C1q receptor that enhances phagocytosis, is detected specifically in human cells of myeloid lineage, endothelial cells, and platelets. J. Immunol. 160:1929-1935.
53. Peiris JS, Porterfield JS. 1979. Antibody-mediated enhancement of Flavivirus replication in macrophage-like cell lines. Nature 282:509-511. http://dx.doi.org/10.1038/282509a0.
54. Daughaday CC, Brandt WE, McCown JM, Russell PK. 1981. Evidence for two mechanisms of dengue virus infection of adherent human monocytes: trypsin-sensitive virus receptors and trypsin-resistant immune complex receptors. Infect. Immun. 32:469-473.
55. Schlesinger JJ, Brandriss MW. 1983. 17D yellow fever virus infection of P388D1 cells mediated by monoclonal antibodies: properties of the macrophage Fc receptor. J. Gen. Virol. 64:1255-1262. http://dx.doi.org/10.1099/0022-1317-64-6-1255.
56. Mason PW, Baxt B, Brown F, Harber J, Murdin A, Wimmer E. 1993. Antibody-complexed foot-and-mouth disease virus, but not poliovirus, can infect normally insusceptible cells via the Fc receptor. Virology 192: 568-577. http://dx.doi.org/10.1006/viro.1993.1073.
57. Hober D, Chehadeh W, Bouzidi A, Wattre P. 2001. Antibodydependent enhancement of coxsackievirus B4 infectivity of human peripheral blood mononuclear cells results in increased interferon alpha synthesis. J. Infect. Dis. 184:1098-1108. http://dx.doi.org/10.1086/323801.
58. Takeda A, Tuazon CU, Ennis FA. 1988. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 242:580-583. http://dx.doi.org/10.1126/science.2972065.
59. Lund O, Hansen J, Soorensen AM, Mosekilde E, Nielsen JO, Hansen JE. 1995. Increased adhesion as a mechanism of antibody-dependent and antibody-independent complement-mediated enhancement of human immunodeficiency virus infection. J. Virol. 69:2393-2400.
60. Fanger NA, Fanger MW, Guyre PM. 1998. Fc receptors, p 886-892. In Roitti I, Delves PJ (ed), Encyclopedia of immunology, 2nd ed. Academic Press, San Diego, CA.
61. Farr GA, Zhang LG, Tattersall P. 2005. Parvoviral virions deploy a capsid-tethered lipolytic enzyme to breach the endosomal membrane during cell entry. Proc. Natl. Acad. Sci. U. S. A. 102:17148-17153. http://dx.doi.org/10.1073/pnas.0508477102.
62. Zadori Z, Szelei J, Lacoste MC, Li Y, Gariepy S, Raymond P, Allaire M, Nabi IR, Tijssen P. 2001. A viral phospholipase A2 is required for parvovirus infectivity. Dev. Cell 1:291-302. http://dx.doi.org/10.1016/S1534-5807(01)00031-4.
63. Fonseca MI, Carpenter PM, Park M, Palmarini G, Nelson EL, Tenner AJ. 2001. C1qR(P), a myeloid cell receptor in blood, is predominantly expressed on endothelial cells in human tissue. J. Leukoc. Biol. 70:793-800.
64. Kaul M, Loos M. 1997. Dissection of C1q capability of interacting with IgG. Time-dependent formation of a tight and only partly reversible association. J. Biol. Chem. 272:33234-33244.
65. Meri S, von Bonsdorff C-H. 1998. Compement fixation test, p 617-619. In Roitt I, Delves PJ (ed), Encyclopedia of immunology, 2nd ed. Academic Press, San Diego, CA.
66. Magro CM, Nuovo G, Ferri C, Crowson AN, Giuggioli D, Sebastiani M. 2004. Parvoviral infection of endothelial cells and stromal fibroblasts: a possible pathogenetic role in scleroderma. J. Cutan. Pathol. 31:43-50. http://dx.doi.org/10.1046/j.0303-6987.2003.0143.x.
67. Pozzuto T, von Kietzell K, Bock T, Schmidt-Lucke C, Poller W, Zobel T, Lassner D, Zeichhardt H, Weger S, Fechner H. 2011. Transactivation of human parvovirus B19 gene expression in endothelial cells by adenoviral helper functions. Virology 411:50-64. http://dx.doi.org/10.1016/j.virol.2010.12.019.
68. Thomson BJ, Weindler FW, Gray D, Schwaab V, Heilbronn R. 1994. Human herpesvirus 6 (HHV-6) is a helper virus for adeno-associated virus type 2 (AAV-2) and the AAV-2 rep gene homologue in HHV-6 can mediate AAV-2 DNA replication and regulate gene expression. Virology 204:304-311. http://dx.doi.org/10.1006/viro.1994.1535.